Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.46 |
| ▸ | GPX4 | P36969 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 7/20 | 0.44 |
| ▸ | CCND1 | P24385 | 7/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3476606 | 0.85 | TRPV1 (0.45) | TRPV1GPX4CDK4CCND1FAAH | |
| SCHEMBL5376050 | 0.84 | TRPV1 (0.47) | TRPV1GPX4FAAH | |
| SCHEMBL5381186 | 0.80 | BAZ2B (0.64) | TRPV1CDK4CCND1FAAH | |
| SCHEMBL5379919 | 0.80 | CDK4 (0.55) | TRPV1GPX4CDK4CCND1FAAH | |
| SCHEMBL5375005 | 0.80 | BAZ2B (0.64) | TRPV1GPX4FAAH | |
| SCHEMBL5376602 | 0.80 | TRPV1 (0.56) | TRPV1GPX4CDK4CCND1FAAH | |
| SCHEMBL21732051 | 0.77 | CDK4 (0.57) | TRPV1CDK4CCND1 | |
| SCHEMBL2274627 | 0.76 | TRPV1 (0.57) | TRPV1 | |
| SCHEMBL5381266 | 0.75 | TRPV1 (0.69) | TRPV1 | |
| SCHEMBL3476549 | 0.75 | BAZ2B (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | claimed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | claimed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | claimed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | TRPV1 853/4885GPX4 3462/4885CDK4 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.